Oral Glycoprotein IIb/IIIa Inhibitors
Authors:
- 1 January 2001
- journal article
- Published by Springer Nature in American Journal of Cardiovascular Drugs
- Vol. 1 (6) , 421-428
Abstract
Despite their promise as orally active potent inhibitors of platelet aggregation, the oral platelet glycoprotein IIb/IIIa inhibitors have failed to provide a reduction in late ischemic events. In...Keywords
This publication has 32 references indexed in Scilit:
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment ElevationNew England Journal of Medicine, 2001
- Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofibanThe Lancet, 1999
- Pharmacodynamic Efficacy, Clinical Safety, and Outcomes After Prolonged Platelet Glycoprotein IIb/IIIa Receptor Blockade With Oral XemilofibanCirculation, 1998
- Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 1998
- A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable AnginaNew England Journal of Medicine, 1998
- First Chronic Platelet Glycoprotein IIb/IIIa Integrin BlockadeCirculation, 1997
- A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)The Lancet, 1996
- Differential Dose-Response to Oral Xemilofiban After Antecedent Intravenous AbciximabCirculation, 1996
- Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary AngioplastyNew England Journal of Medicine, 1994
- Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patientsBMJ, 1994